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Abstract
Background: Intensive care unit (ICU) admission of adults with cystic fibrosis (CF) is
controversial because of poor outcome. This appraisal needs re-evaluation following recent
changes in both CF management and ICU daily practice. Objectives were to determine long-term
outcome of adults with CF admitted in ICU and to identify prognostic factors.
Methods: Retrospective multicenter study of 60 ICU hospitalizations for 42 adult CF patients
admitted between 2000 and 2003. Reason for ICU admission, ventilatory support provided and
one-year survival were recorded. Multiple logistic analysis was used to determine predictors of
mortality.
Results: Prior to ICU admission, all patients (mean age 28.1 ± 8 yr) had a severe lung disease (mean
FEV1 28 ± 12% predicted; mean PaCO2 47 ± 9 mmHg). Main reason for ICU hospitalization was
pulmonary infective exacerbation (40/60). At admission, noninvasive ventilation was used in 57% of
cases and was successful in 67% of patients. Endotracheal intubation was implemented in 19
episodes. Overall ICU mortality rate was 14%. One year after ICU discharge, 10 of the 28 survivors
have been lung transplanted. Among recognized markers of CF disease severity, only the annual
FEV1 loss was associated with a poor outcome (HR = 1.47 [1.18–1.85], p = 0.001). SAPSII (HR =
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1.08 [1.03–1.12], p < 0.001) and endotracheal intubation (HR = 16.60 [4.35–63.34], p < 0.001) were
identified as strong independent predictors of mortality.
Conclusion: Despite advanced lung disease, adult patients with CF admitted in ICU have high
survival rate. Endotracheal intubation is associated with a poor prognosis and should be used as the
last alternative. Although efforts have to be made in selecting patients with CF likely to benefit from
ICU resources, ICU admission of these patients should be considered.
Background
Cystic fibrosis (CF) is a common life-shortening genetic
disorder among Caucasians caused by mutations of the
cystic fibrosis transmembrane conductance regulator gene
(CFTR), leading to respiratory, pancreatic, and gastro-
intestinal disorders [1]. Forty years ago, CF was invariably
a fatal disease of early childhood. Although the disease
remains incurable, advances in CF chronic disease man-
agement (including establishment of specialized care
centers, improvement in nutritional care, home ventila-
tory support and organ transplantation) resulted in
increasing the median survival age to 35.1 years [2,3]. In
2003 almost 40% of CF patients were older than 18, cor-
responding to an adult population with CF of 2,200 indi-
viduals in France and 10,000 in the United States
illustrating the significant changes in the demographics of
CF during the last two decades [3,4]. As severity of CF pul-
monary disease usually increases with age, adults are a
group at higher risk for acute respiratory complications
that are more likely to be life threatening and to request
ICU hospitalization [2].
In the 80s, ICU admission of adult patients with CF was
restricted since it was associated with a high mortality rate
(69% in ICU; 81% at one year), especially when the
patients required endotracheal intubation [5]. In the 90s,
two studies reported an improved survival rate for this
population in ICU. Sood et al. reported an ICU mortality
rate of 32% and Vedam et al. showed that 55% of ICU-
hospitalized CF patients died in hospital [6,7]. Such dif-
ferences in outcome may be related to heterogeneity of
studied populations and disparities in ICU admission cri-
teria or care. For instance, during the long time periods in
which both studies took place (1991–2000 and 1988–
2003, respectively), major changes occurred in the respi-
ratory management of exacerbations of chronic cardiopul-
monary diseases, including CF. In the last decade,
prognosis of acute exacerbations of chronic obstructive
pulmonary disease (COPD) dramatically improved due
to the increasing implementation of noninvasive ventila-
tion (NIV) [8]. However, time required for the education
and training of health careers explains that its daily prac-
tice was generalized in ICU only since 1999 [9]. Impact of
NIV implementation has been poorly evaluated for CF
patients hospitalized in ICU.
Characterizing the adult population recently admitted in
ICU and its outcome may help to understand needs and
to optimize care for this steadily growing patient group. In
this retrospective multicenter study, we have analyzed rea-
sons for ICU admission, initial ventilatory support pro-
vided and long-term survival of adult patients with CF. We
also determined predictive factors of mortality, which
may help to define ICU admission criteria for this popu-
lation.
Study population and methods
Patient selection
Nineteen ICUs of the Paris area (a 10 million people pop-
ulation including approximately 200 adult CF patients)
were contacted to identify adult CF patient admissions
between January 2000 and June 2003 [4]. Two independ-
ent investigators performed report selection by consulting
and reviewing ICU clinical databases. Only one episode
was considered when patients were transferred from one
to another ICU center. CF diagnosis was based on medical
history, repeated sweat chloride tests and identification of
CFTR gene mutations. CF patients who received solid
organ transplant before ICU entry were not included in
the study. Decisions for ICU admission involved both
intensivists and CF clinicians. Patients received standard-
ized care, i.e. antibiotics, nutritional support and chest
physiotherapy, according to international guidelines for
CF disease [2].
Data collection
The following data were collected by reviewing patient
medical charts: CFTR genotype, extra-pulmonary manifes-
tations of CF and features of airway chronic bacterial col-
onization. The severity of respiratory functional
impairment was assessed by using (i) the best baseline
lung function test performed during a stable outpatient
visit within the 6 months preceding ICU admission, (ii)
the slope in lung function decline, calculated from all
available lung function tests recorded within the 5 years
preceding the entry in the study. Body mass index (BMI)
was used as a marker of nutritional state. Home ventila-
tory support and registration on lung transplant list were
recorded as indirect severity indexes.
The slope of lung function decline was calculated individ-
ually using linear regression, with a required R2 > 0.40, a
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minimum follow-up time of two years and a minimum of
4 points for each variable. CFTR genotypes were grouped
into severity classes according to the probable functional
consequences on CFTR protein: "mild" for patients with
at least one mutation of classes IV or V; "severe" for
patients with two mutations of classes I, II or III; and "not
determined" for patients with only one identified muta-
tion of class I, II or III [10].
Demographics, number of previous admissions in ICU,
admission source and motive, arterial blood gases and
simplified acute physiology score II (SAPSII) were
recorded at ICU entry [11]. The need for, the type, the tim-
ing and the duration of ventilatory support, the length of
ICU stay and patient immediate outcome were also col-
lected.
Six-month and one-year follow-up of patients surviving to
ICU hospitalization were obtained from clinicians who
usually cared for the patients. In the case of multiple ICU
hospitalizations within the study period, the first ICU
admission was considered as the index hospitalization.
Statistical methods
All results are expressed as mean ± SD. Comparisons of
the characteristics and outcome of the patients according
to ventilatory support were made using nonparametric
statistical methods (Wilcoxon's and exact chi-square tests)
because of the non-normal distribution of several varia-
bles and the small numbers of patients in the groups of
interest.
To identify prognostic factors, analyses were based on epi-
sodes since several patients underwent re-admissions in
ICU during the study period. Cox proportional hazard
regression methods were used to determine the associa-
tion between patient characteristics and outcome. Multi-
level modeling was performed to account for the
clustering effect of patients (patients having several
admissions). Factors that were associated with mortality
at p value below 0.10 in univariate analyses were consid-
ered to enter into the multivariate Cox models. Results are
expressed using the hazard ratio (HR), and the 95% con-
fidence interval (CI). STATA software (StataCorp. Stata
Statistical Software. Release 7.0, Stata Corporation, Col-
lege Station-TX-, 2001) was used.
Results
Patients
60 admissions corresponding to 42 adult patients with CF
(ranging in age from 18 to 54 yr [mean: 28.1 yr]) were
identified in 6 medical ICUs of University Hospitals
between January 2000 and June 2003. Thirteen ICUs did
Initial ventilatory support for the 60 ICU hospitalizations according to reason for admissionFigu e 1
Initial ventilatory support for the 60 ICU hospitaliza-
tions according to reason for admission. Other causes 
were coma (epilepsy, n = 2, and benzodiazepin intoxication, n 
= 2) and follow-up after surgical treatment of pneumothorax 
(n = 2).
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Table 1: Characteristics of the population before the first ICU 
hospitalization
Age, yr 28.1 ± 7.8
Sex, M/F 25/17
Severity of CFTR genotype, S/M/ND 30/4/8
BMI, Kg/m2 17.8 ± 2.1
Extra-pulmonary involvement
Pancreatic insufficiency 37 (88%)
Diabetes 8 (19%)
Cirrhosis 3 (7%)
Chronic airway colonization
P. aeruginosa 39 (93%)
B. cepacia complex 2 (5%)
Lung function in stable state
FEV1, % predicted 28 ± 12
FVC, % predicted 45 ± 15
TLC, % predicted 98 ± 22
Room air PaO2, mmHg 62 ± 15
Room air PaCO2, mmHg 47 ± 9
Room air SaO2, % 89 ± 8
Annual FEV1 loss, % predicted/yr 4.21 ± 2.65
Home ventilatory support
Long term oxygenotherapy alone 12 (29%)
Noninvasive ventilation 10 (24%)
Patients awaiting lung transplant 9 (21%)
Values are expressed in mean ± SD or number (percentage of group).
Abbreviations: ICU: intensive care unit; M: male; F: female; CFTR: 
cystic fibrosis transmembrane conductance regulator; S: severe; M: 
mild; ND: not determined; BMI: body mass index; FEV1: forced 
expiratory volume in one second; FVC: forced vital capacity; TLC: 
total lung capacity; PaO2: arterial oxygen tension; PaCO2: arterial 
carbon dioxide tension; SaO2: arterial oxygen saturation.
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not admit adult patients with CF during the study period.
Among the identified population, 9 patients had more
than one admission (maximum five), sometimes in differ-
ent ICUs. Three patients had experienced ICU care prior to
the study period. Mean SAPSII was 21 ± 16 and length of
ICU stay was 7.6 ± 7.4 days.
Characteristics of the 42 patients with CF in stable state at
the last evaluation before their first ICU admission are
shown in Table 1. This population stood out by the sever-
ity of the pulmonary disease, characterized by severe
bronchial obstruction (FEV1: 28 ± 12% predicted value for
height, age and sex with a mean slope of annual FEV1 loss
of 4.21 ± 2.65% predicted/yr, calculated on 4.1 ± 1.4 yr
and 12 ± 7 points), chronic hypoxemia and hypercapnia,
low body mass index and almost constant chronic airway
colonization with P. aeruginosa (93%). Before ICU admis-
sion, about half of the patients were receiving home ven-
tilatory support (long-term oxygenotherapy or
noninvasive ventilation) and one fifth was awaiting lung
transplantation.
Admissions
Three respiratory etiologies represented 90% of entry
motives in ICU: pulmonary infective exacerbation (n = 40
episodes), moderate to massive hemoptysis (n = 9 epi-
sodes) and pneumothorax (n = 5 episodes). Six episodes
of hemoptysis required embolization of bronchial arteries
and four episodes of pneumothorax needed surgery,
underlying the severity of clinical presentation. The other
causes for ICU hospitalization were coma (n = 4) (epi-
lepsy, benzodiazepin intoxication) and follow-up after
surgical treatment of pneumothorax (n = 2).
ICU admission sources were pulmonary wards (35/60),
emergency rooms (20/60), mobile emergency medical
units (4/60) and department of surgery (1/60). Sources
and reasons for ICU hospitalization of CF patients were
tightly associated. While 75% of patients with pulmonary
infective exacerbations came from pulmonary wards,
admissions for hemoptysis, pneumothorax and other
causes were more likely direct (67%, 100% and 50%,
respectively).
Last stable spirometric values were significantly higher in
patients admitted for hemoptysis (FEV1: 35 ± 15%) than
in patients hospitalized for pulmonary infective exacerba-
tions (FEV1: 25 ± 7%, p = 0.014) or for pneumothorax
(FEV1: 22 ± 2%, p = 0.025).
ICU ventilatory support
Initial ventilatory assistance was analyzed for the 60 epi-
sodes according to admission motives. As illustrated in
Figure 1, only one patient required ventilatory support in
Table 2: Characteristics and outcome according to initial ventilatory support
IV NIV SB
No. of episodes 8 34 18
Age, yr 29.8 ± 9.2 27.2 ± 8.1 28.9 ± 5.9
Sex, M/F 5/3 20/14 13/5
BMI, Kg/m2 17.5 ± 0.8 17.3 ± 1.8 18.2 ± 2.5
Lung function in stable state
FEV1, % predicted 28 ± 13 24 ± 6 32 ± 14
‡
Room air PaO2, mmHg 67 ± 22 55 ± 12 68 ± 9
Room air PaCO2, mmHg 46 ± 10 50 ± 8 44 ± 3
‡
Annual FEV1 loss, % predicted/yr 3.63 ± 3.62 4.33 ± 2.46 3.76 ± 2.46
Home NIV 3 (37%) 18 (53%) 2 (11%)
Waiting for lung transplant 3 (37%) 11 (32%) 1 (6%)
Acute episode characteristics
SAPSII 35 ± 28 23 ± 13* 10 ± 4§
PaCO2 at entry, mmHg 102 ± 60 70 ± 20
† 49 ± 9§
Arterial pH at entry 7.22 ± 0.18 7.36 ± 0.07† 7.40 ± 0.05
Admission for pulmonary exacerbation 7 (87%) 29 (85%) 4 (22%)
Length of ICU stay, days 9.6 ± 10.9 8.9 ± 7.7 4.1 ± 3.2
ICU mortality, number of patients (%) 3 (37%) 8 (24%) 0 (0%)
Values are expressed in mean ± SD or number (percentage of group).
Symbols: *: p = 0.067 and †: p < 0.01 for comparison between IV and NIV; ‡: p = 0.005 for comparison between spontaneous breathing and NIV 
and §: p < 0.001 for comparison between spontaneous breathing and IV or NIV.
Abbreviations: ICU: intensive care unit; NIV: noninvasive ventilation; IV: invasive ventilation; SB: spontaneous breathing; M: male; F: female; BMI: 
body mass index; FEV1: forced expiratory volume in one second; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; SAPSII: 
simplified acute physiology score II.
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the group of patients admitted for hemoptysis or pneu-
mothorax.
Noninvasive ventilation (NIV) was the main ventilatory
support, initiated at admission in 34 out of the 60 epi-
sodes for 7.4 ± 6.5 days. Endotracheal intubation was
undertaken before ICU admission in 3 cases, at ICU entry
in 5 cases and during ICU stay (at day 3.8 ± 3.9) in 11
cases because of NIV failure. Thus, invasive ventilation
(IV) was required in 19 of the 60 episodes for 7.3 ± 8.8
days.
In order to identify factors that may predict the need for
and the efficacy of ventilatory support, patients' character-
istics were compared according to the initial ventilatory
support provided (Table 2) and success or failure of NIV
(Table 3). At ICU entry, patients requiring IV had a more
severe presentation reflected by higher SAPSII, lower arte-
rial pH and higher PaCO2. No features of chronic CF lung
disease were predictive for the risk of initial intubation
(Table 2). Surprisingly, patients with successful NIV,
defined by ICU discharge without endotracheal intuba-
tion, had a more severe basal lung function than patients
with NIV failure (22 ± 5 vs. 27 ± 8% pred, p = 0.02 for
FEV1; 52 ± 8 vs. 47 ± 8 mmHg, p = 0.07 for resting PaCO2)
although no difference appeared in the severity of clinical
presentation at ICU entry between both groups (Table 3).
Similar findings were found when the successful NIV
group was compared to a group composed of both
patients with initial IV and patients with NIV failure (data
not shown).
Outcome
Six of the 42 patients (14%) died during their first ICU
admission (Fig 2). Mortality rate was 27.5% for patients
admitted for pulmonary infective exacerbation while all
patients hospitalized for hemoptysis, pneumothorax,
post-surgical care or coma survived. Episodes requiring IV
had an ICU-mortality rate of 58%. Outcome of patients of
the NIV failure group was particularly dramatic, as 8 out
of 11 died (Table 3).
One-year follow-up was completed for all patients (Fig 2).
Mortality rate increased to 26% at six month and 33% at
one year. One-year survival rate was 58% for the subset of
patients with pulmonary infective exacerbations. The
patients who survived IV were still living at one year; four
of them underwent lung transplantation. ICU stay led to
a change in chronic management in most survivors, with
the implementation of home NIV or home oxygen use in
28% and 25% of the patients, respectively; 8 patients were
newly listed for lung transplantation. Among the patients
awaiting lung transplantation before the first ICU hospi-
talization, two died and seven received a graft. The mean
Table 3: Characteristics and outcome according to NIV effectiveness
Success Failure
No. of episodes 23 11 p value
Age, yr 26.4 ± 6.9 28.8 ± 10.2 ns
Sex, M/F 15/8 5/6 ns
BMI, Kg/m2 17.0 ± 1.5 17.9 ± 2.3 ns
Lung function in stable state
FEV1, % predicted 22 ± 5 27 ± 8 0.02
Room air PaO2, mmHg 54 ± 13 58 ± 11 ns
Room air PaCO2, mmHg 52 ± 8 47 ± 8 0.07
Annual FEV1 loss, % predicted/yr 4.27 ± 2.55 4.44 ± 2.39 ns
Home NIV 14 (61%) 4 (36%) 0.07
Waiting for lung transplant 8 (35%) 3 (27%) ns
Acute episode characteristics
SAPSII 21 ± 9 28 ± 20 ns
PaO2 at entry, mmHg 60 ± 21 66 ± 14 ns
PaCO2 at entry, mmHg 70 ± 19 70 ± 24 ns
Arterial pH at entry 7.37 ± 0.06 7.35 ± 0.09 ns
Admission for pulmonary exacerbation 19 (83%) 10 (91%) ns
Length of NIV, days 9.1 ± 6.8 3.8 ± 3.9 0.02
Length of ICU stay, days 9.1 ± 6.8 8.6 ± 9.5 ns
ICU mortality, number of patients (%) 0 (0%) 8 (73%) <0.001
Values are expressed in mean ± SD or number (percentage of group). Successful NIV represent episodes requiring NIV use and leading to ICU 
discharge without endotracheal intubation; NIV failure are episodes requiring both NIV and IV use. Abbreviations: ICU: intensive care unit; NIV: 
noninvasive ventilation; M: male; F: female; BMI: body mass index; FEV1: forced expiratory volume in one second; PaO2: arterial oxygen tension; 
PaCO2: arterial carbon dioxide tension; SAPSII: simplified acute physiology score II.
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time between ICU discharge and lung transplantation (n
= 10) was 3.0 ± 3.4 months although patients were on the
waiting list for 26.5 ± 24.9 months before ICU hospitali-
zation.
Predictors of mortality
The results of the univariate proportional hazards assess-
ment of risk factors for death are exhibited in Table 4. The
need for invasive ventilation was the factor associated
with the highest risk of dying (HR = 16.8, 95% CI 4.93 to
57.38, p = 0.001). Among the factors reflecting CF disease
severity, a low resting PaO2 and an accelerated rate in
annual FEV1 loss were also associated with an increased
risk of death. Age, sex, BMI, severity of CFTR genotype,
extra-pulmonary involvements, airway chronic bacterial
colonization and last stable spirometric data (Fig 3) were
not predictive for outcome.
The results of the multivariate analysis are presented in
Table 5. Three variables, the annual FEV1 loss, SAPSII and
endotracheal intubation, emerged as significant inde-
pendent risk factors for death in the final model after
adjusting for confounders. Results of the statistical analy-
ses were unchanged when only the patients with pulmo-
nary infectious exacerbations were considered.
Discussion
Decision to admit adult patients with CF in ICU is still
controversial, mostly because of futility reasons. In this
multicenter study, we analyzed 60 ICU hospitalizations of
42 adult patients with CF admitted between 2000 and
2003. We have shown that NIV was the main ventilatory
support, used in 57% of episodes and 73% of pulmonary
infective exacerbations. Despite the pre-existing severe CF
lung disease, both ICU and one-year mortality rates were
relatively low (14% and 33%, respectively). Severity of
acute respiratory failure (reflected by SAPSII and the need
for endotracheal intubation) and rapid progression of CF
lung disease (illustrated by the yearly decline in percent
predicted FEV1) were strong independent predictors of
mortality.
The increased survival age of patients with CF predicts a
shift in patients with life-threatening complications from
pediatric ICU to adult ICU [3]. However, effectiveness of
ICU admission is still questioned for adult CF patients
with advanced lung disease. Since the first report from
Davis et al. [5], ICU survival of patients with CF has
greatly improved. In the North Carolina hospital series,
the retrospective analysis of 106 adult CF patient admis-
sions between 1990 and 1998 (after excluding 30 epi-
sodes for antibiotic desensitization) showed that 70% of
patients were discharged alive from ICU [6]. A recent
study conducted between 1997 and 2001 confirmed these
results in a cohort of 23 adult patients with CF (ICU sur-
vival rate of 74%) [12]. In the current multicenter report,
although patients were older (28 yr old) and harbored
more severe lung function than the patients of previous
studies, 82% of ICU admissions conducted to ICU dis-
charge. This result is similar to the 17% ICU mortality rate
reported in a general ICU population (100,544 patients)
hospitalized in the same area in the 90's [13].
This drop in mortality rate may partially result from the
significant increase in NIV use in the ICU management of
CF patients, despite the absence of evidence-based guide-
lines. Indeed, this important change in ICU daily practice
was essentially based on randomized trials that demon-
strated significant reduction in complication and mortal-
ity rates for patients with COPD exacerbation [8,14].
ICU, six-month and one-year outcome following the first  admissionFigure 2
ICU, six-month and one-year outcome following the 
first ICU admission. When a patient was admitted several 
times, the first hospitalization was used as index hospitaliza-
tion. Outcome is expressed both in number of patients and 
percentage of the total population.
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Table 5: Multivariate analysis for predictors of mortality
Predictor Hazard Ratio [95% CI] p Value
Annual FEV1 loss 1.47 [1.18–1.85] 0.001
SAPSII 1.08 [1.03–1.12] <0.001
Endotracheal intubation 16.60 [4.35–63.34] <0.001
Values are expressed as hazard ratios, 95% confidence intervals (CI) for the hazard ratios and p-values. When a patient was admitted several times, 
episodes were analyzed as new and independent events.
Abbreviations: FEV1: forced expiratory volume in one second; SAPSII: simplified acute physiology score II.
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Recent evaluation of routine NIV implementation for
these COPD patients in ICU showed an increased use
from 30% in 1995 to almost 90% in 1999 and a drastic
concomitant decrease in in-hospital mortality (from 24%
in 1994 to 11% in 2002) [9]. The current study confirms
that this new ICU practice also affects respiratory care of
adult CF population. Hence, NIV was used in less than
30% of CF patients admitted in the 90's for pulmonary
exacerbations and in 60% of cases in the study by Ellafi et
al. conducted between 1997 and 2001 [6,7,12]. Here we
show that NIV was the main ventilatory support, used in
almost 75% of admissions for pulmonary infective exac-
erbations, and was efficient in two-thirds of the cases.
Interestingly, NIV success was more frequent among
patients with prior home NIV (Table 3), suggesting the
importance of education and chronic respiratory manage-
ment. An alternative explanation is that these patients
were adapted to chronic hypercapnia, hence better suited
for worsening hypercapnia than patients with pre-existing
normal acid-base status.
NIV failure led to endotracheal intubation and was asso-
ciated with a very poor outcome (Table 3). The current
study showed an overall ICU mortality rate of 58% for
patients requiring IV, confirming that prognosis of intu-
bated CF patients has not improved during the last thirty
years. Indeed, the study conducted in the 70's and the
three ICU-series performed in the 90's concerning either
pediatric or adult patients reported an ICU-mortality rate
of 65%, 61%, 45% and 61%, respectively, for CF patients
requiring endotracheal intubation [5-7,15]. Our results of
both univariate and multivariate analyses also strongly
highlight the pejorative prognostic value of invasive ven-
tilation (Tables 4 and 5). Conversely, all patients who sur-
vived despite IV requirement were still living one year
after ICU discharge, half of them having been lung trans-
planted.
Thus, hospitalization of adult CF patients in ICU may fur-
thermore be justified by both the possibility to adapt
chronic management (like implementing home ventila-
tory support) and the perspective of long-term survival
with lung transplantation. In the Sood's study, two thirds
of the ICU survivors (20/33) underwent lung transplanta-
tion within one year [6]. In our series, 10 of the 28 long-
term survivors had received lung transplant, most of them
within 6 months after ICU discharge. These results may
indicate that CF patients who have been hospitalized in
Table 4: Univariate analysis of factors associated with mortality
Hazard Ratio [95% CI] p value
Factors related to severity of CF disease in stable state
Age 1.02 [0.91–1.14] 0.701
Sex 1.39 [0.69–2.77] 0.347
BMI 0.95 [0.80–1.13] 0.614
Diabetes 0.79 [0.34–1.85] 0.595
Severity of CFTR genotype 0.84 [0.29–2.42] 0.750
P. aeruginosa colonization 1.49 [0.40–5.55] 0.544
B. cepacia complex colonization 1.95 [0.77–4.89] 0.153
FEV1, % predicted 0.97 [0.93–1.02] 0.289
Room air PaO2 0.96 [0.93–0.99] 0.041
Room air PaCO2 1.01 [0.95–1.07] 0.646
Annual FEV1 loss, % predicted/yr 1.25 [1.04–1.52] 0.019
Long-term oxygenotherapy 1.66 [0.53–5.17] 0.375
Home NIV 1.19 [0.30–4.64] 0.794
Factors related to ICU hospitalization
SAPSII 1.05 [1.02–1.08] 0.001
PaO2 at entry 1.004 [0.999–1.009] 0.065
PaCO2 at entry 1.01 [1.01–1.02] 0.001
Initial noninvasive ventilation 12.78 [1.63–100.25] 0.015
Initial intubation 14.57 [1.42–149.22] 0.024
Intubation during stay 16.82 [4.93–57.38] 0.001
Values are expressed as hazard ratios and 95% confidence intervals (CI) for the hazard ratios. When a patient was admitted several times, episodes 
were analyzed as new and independent events.
Abbreviations: CF: cystic fibrosis; ICU: intensive care unit; BMI: body mass index; CFTR: cystic fibrosis transmembrane conductance regulator; 
FEV1: forced expiratory volume in one second; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; NIV: noninvasive ventilation; 
SAPSII: simplified acute physiology score II.
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Lung function parameters in stable state prior to ICU entry according to (A) reason for ICU admission and (B) ICU mortalityFigure 3
Lung function parameters in stable state prior to ICU entry according to (A) reason for ICU admission and (B) 
ICU mortality. Boxes are interquartile ranges. Bars show range from 10th to 90th percentiles. When a patient was admitted 
several times, episodes were considered as new and independent events. Other causes were coma (epilepsy, n = 2, and benzo-
diazepin intoxication, n = 2) and follow-up after surgical treatment of pneumothorax (n = 2). Abbreviations: FEV1: forced expir-
atory volume in one second.
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ICU are still good candidates for lung transplants. Further-
more, as previously shown [16], we found that acute epi-
sodes requiring IV did not adversely affect the one-year
survival benefit after lung transplantation (data not
shown).
Severity of CF disease is usually related to several parame-
ters such as CFTR genotype, lung function tests, airway
bacterial colonization, gender and age [17-20]. Surpris-
ingly, none of these recognized prognostic factors were
associated with ICU outcome. Contrasting with previous
findings [12,21], no association between B. cepacia com-
plex colonization and ICU or long-term survival was
found, probably because of the small number of patients
infected with this bacteria. Similarly, FEV1 value below
30% pred, which serves to consider lung transplantation
referral in American and European guidelines [22,23], was
not linked to ICU mortality. Only accelerated rate of
annual FEV1 loss discriminated patients with a higher risk
of death although no cut-off value could be determined.
Among CF patients, this dynamic variable has been
already associated with higher risk of death in a subgroup
of patients with severe lung disease (FEV1 below 30%
pred) [24] but not in a general population heterogeneous
for lung function (mean FEV1 68% pred) [21]. Differences
of studied populations may explain this apparent discrep-
ancy. Hence, rate of decline in lung function is variable
along CF pulmonary disease course [25] and it is likely
that a rapid FEV1 decline may be more accurate to predict
mortality in patients with end-stage lung disease. In this
particular subgroup of CF patients, occurrence of an acute
pulmonary complication might be poorly tolerated. A
high-resolution computed tomography study suggested
that the loss of FEV1 may reflect the severity of bronchial
wall thickening and atelectasis-consolidation in CF
patients [26]. These features could partially explain the
difficulty to reverse severe hypercapnia in some patients
despite aggressive ventilatory support.
There are some limits to this study. Thus, we did not con-
sider some important parameters, as they were not con-
tained in medical charts such as patient wishes and
quality of life after ICU stay. Because our study relied on
observational data, rather than on the results of a prospec-
tive trial, the potential for patient selection bias, although
small, remains. Nevertheless, patients with CF benefit
from regular and standardized medical care in specialized
centers that allow precise evaluation of their clinical char-
acteristics at ICU admission and a complete reliable long-
term follow-up. The absence of well-defined ICU admis-
sion criteria is another important variable to consider for
study analysis. However, all ICU admissions analyzed in
this study occurred in University Hospitals with Pulmo-
nary Departments that routinely use NIV, suggesting that
none of the ICU admission might have resulted from the
absence of resources in the pulmonary wards. Analysis of
ICU admission sources sustains this statement, as 75% of
patients with pulmonary infective exacerbations came
from pulmonary wards of the same hospitals. Moreover,
comparison of patient characteristics between the 6 ICUs
showed no differences in terms of chronic and acute sever-
ity of patients (data not shown). A recent French study has
shown that CF patients with pulmonary exacerbations
admitted in ICU were significantly more severe than those
treated in the pulmonary ward of the same hospital [12],
underlying that request for ICU admission is mainly trig-
gered by clinical instability, the need for close monitoring
or the probability for endotracheal intubation.
Conclusion
Overall mortality of adult CF patients hospitalized in ICU
continues to decrease in recent years, despite admission of
older patients with advanced lung disease. Decision to
admit these patients in ICU should be considered as sur-
viving to ICU discharge did not compromise opportunity
for lung transplantation. Endotracheal intubation was
associated with high mortality rate and the use of NIV
should be strongly recommended. Parameters used to
assess severity of chronic pulmonary disease are poor pre-
dictors for ICU outcome and future studies focusing on
more relevant markers of CF phenotype are needed to
define appropriate ICU admission criteria.
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